The FDA has cleared Agenus (NASDAQ:AGEN)
unit, AgenTus Therapeutics’ IND application for an allogeneic iNKT
therapy, as a potential therapy for treatment of patients with COVID-19.
A clinical trial is expected to commence shortly.
https://seekingalpha.com/news/3579526-agenus-on-go-to-start-study-of-cell-therapy-in-covidminus-19
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.